Oncology Surveillance Follow-Up Note (Post-Treatment)

Oncology Surveillance Follow-Up (Post-Treatment)

(Use this template for patients post-curative or disease-controlling therapy who are in surveillance or on long-duration maintenance therapy. Emphasize interval changes since last visit and avoid restating unchanged historical data. Use standardized tokens for missing information: "Unknown," "Not documented in available records," "Patient unsure," or "Records requested from [source] on [date].")

Date: [date of encounter]

Patient: [full name]

Provider: [name and credentials]

Visit Type: Oncology Surveillance Follow-Up (Post-Treatment)

Modality: [in-person / video / phone] (Note interpreter use if applicable)

Care Team: [relevant specialists involved in this patient's care]

Cancer Surveillance Snapshot

• Primary cancer: [site, histology, stage or risk classification with staging system and date]
• Key biomarkers: [biomarkers relevant to prognosis or surveillance with values and dates]
• Treatment summary: [modalities received with dates; include cumulative doses only when relevant to late-effect monitoring]
• Current status: [Post-curative-intent therapy, surveillance phase / On maintenance therapy (specify)]
• Last objective assessment: [modality] on [date] showed [findings]
• Next due surveillance: [items with due dates and responsible clinician]

(If key details are missing: "Snapshot incomplete—records requested from [source]")

Interval History

One-liner: [Time since treatment completion], [time since prior visit], currently [on maintenance therapy / not on active therapy].

• New or changed symptoms: [symptom description with onset, trajectory, severity, and functional impact] (Prioritize interval changes; avoid repeating unchanged symptoms)
• Recurrence-focused review: [constitutional symptoms, new focal pain, respiratory symptoms, GI/GU changes, neurologic symptoms, new masses or skin changes as relevant to cancer type] (Document pertinent negatives for high-yield red flags)
• Late-effect symptoms: [symptoms tied to specific treatment exposures such as cardiac, neuropathy, endocrine, bone health, lymphedema, cognitive or mood changes] (Include severity and functional impact)
• Functional status: [ECOG score or functional description] | [work, ADLs, exercise capacity]
• Maintenance therapy: [therapy name, adherence, tolerability, side effects] (If applicable)
• Interim events: [ED visits, hospitalizations, new diagnoses, new family history since last visit]

Objective

• Vitals: [BP, HR, Temp, RR, SpO2, weight with trend if clinically relevant]
• Focused exam: [general appearance; primary tumor site findings; regional lymph node survey; treatment-related findings such as lymphedema, fibrosis, neuropathy, or surgical scar status; other pertinent systems]
• Performance status: [ECOG 0–4 or Karnofsky %]
• Data reviewed: [imaging, pathology, labs with dates and key findings; note if independently interpreted] (If no new data: "No new interval imaging or labs since last visit")
• Data ordered today: [tests ordered with indication, due date, and ordering responsibility]

Assessment

Primary malignancy: [No clinical or radiographic evidence of recurrence / Indeterminate findings requiring follow-up / Evidence of recurrence] based on [exam and data with dates]. [Recurrence risk context if known]. Candidate for salvage therapy if recurrence detected: [yes / no / conditional].

Late effects: [Active late effects requiring monitoring or intervention, each linked to relevant treatment exposure]

Survivorship issues: [Relevant comorbidities or health maintenance issues with responsible clinician noted]

(Use precise language—distinguish "no evidence of disease on imaging dated [date]" from unsupported terms like "cured" or "in remission")

Plan

Surveillance schedule: [Clinic follow-up cadence and endpoint; imaging and procedure schedule with modalities, due dates, and guideline basis or individualized rationale; tumor markers if evidence-based for this cancer; responsibility assignment]

Late-effect monitoring: [Monitoring plans tied to treatment exposures: cardiac monitoring timing, bone health assessment, neuropathy management, endocrine monitoring, lymphedema care, cognitive/mood support as applicable]

Health maintenance: [Vaccinations, age-appropriate screening, lifestyle counseling; note whether oncology or PCP responsible]

Referrals and coordination: [Referrals placed; PCP communication summary; missing records with interim plan and reconciliation date]

When to call: [Cancer-relevant red flags: rapidly progressive pain, new neurologic deficits, cord compression symptoms, fever if immunocompromised, new masses, concerning bleeding]

Follow-up: [Next visit timing and pre-visit testing required] (If surveillance de-escalated or declined, document shared decision-making rationale)